Tanaka F, Abe M, Akiyoshi T, Nomura T, Sugimachi K, Kishimoto T, Suzuki T, Okada M
Department of Clinical Genetics, Medical Institute of Bioregulation, Kyushu University, Oita, Japan.
Cancer Res. 1997 Apr 1;57(7):1335-43.
Interleukin-6 (IL-6) was found to function as a late-acting killer helper factor in the differentiation of CTLs. In the model of tumor-bearing mice, the systemic administration of recombinant IL-6 was found to mediate the antitumor effect on the immunogenic murine tumors via the in vivo induction of murine CTLs but not on the poorly immunogenic murine tumors in our previous study. However, an in vivo experimental model capable of analyzing the anti-human tumor effect via the in vivo induction of human CTLs has not yet been established. Therefore, in the present study, severe combined immunodeficient mice were given human peripheral blood lymphocytes (SCID-PBL/hu), and thereafter human tumor cells were administered i.p. into these SCID-PBL/hu mice as a model of human patients with cancer. When these SCID-PBL/hu mice bearing allogeneic human CESS B blastoid tumor cells were treated in vivo with recombinant adenovirus vector expressing IL-6 cDNA, both the induction of CD8+ human CTLs against CESS cells in the spleen cells and peritoneal exudate cells and a prolongation in the survival of these mice were observed. Furthermore, SCID-PBL/hu mice were given peripheral blood lymphocytes from patients with cancer (gastric or rectal cancers) and autologous human tumor cells. The in vivo administration of recombinant adenovirus vector expressing IL-6 cDNA induced CD8+ human CTLs specific for autologous human tumor cells from human precursor T cells. The in vivo injection of the IL-6 gene also inhibited growth and metastasis in autologous human cancers. Based on the above findings, the experimental model using SCID-PBL/hu mice and the IL-6 gene delivered in vivo by an adenovirus vector might therefore provide a new strategy capable of analyzing an anti-human tumor effect and the in vivo induction of human CTLs by cytokine gene therapy without using the human body.
白细胞介素-6(IL-6)被发现作为一种晚期作用的杀伤辅助因子参与细胞毒性T淋巴细胞(CTL)的分化。在荷瘤小鼠模型中,我们之前的研究发现,全身给予重组IL-6可通过在体内诱导小鼠CTL介导对免疫原性小鼠肿瘤的抗肿瘤作用,但对免疫原性较差的小鼠肿瘤则无此作用。然而,尚未建立一种能够通过在体内诱导人CTL来分析抗人肿瘤作用的体内实验模型。因此,在本研究中,给严重联合免疫缺陷小鼠输入人外周血淋巴细胞(SCID-PBL/hu),然后将人肿瘤细胞腹腔注射到这些SCID-PBL/hu小鼠体内,以此作为人类癌症患者的模型。当用表达IL-6 cDNA的重组腺病毒载体对这些携带异基因人CESS B淋巴母细胞瘤细胞的SCID-PBL/hu小鼠进行体内治疗时,观察到脾脏细胞和腹腔渗出细胞中针对CESS细胞的CD8 +人CTL的诱导以及这些小鼠存活期的延长。此外,给SCID-PBL/hu小鼠输入癌症(胃癌或直肠癌)患者的外周血淋巴细胞和自体人肿瘤细胞。表达IL-6 cDNA的重组腺病毒载体的体内给药可从人前体T细胞诱导出针对自体人肿瘤细胞的CD8 +人CTL。IL-6基因的体内注射也抑制了自体人癌症的生长和转移。基于上述发现,使用SCID-PBL/hu小鼠和通过腺病毒载体在体内递送IL-6基因的实验模型可能因此提供一种新策略,能够在不使用人体的情况下通过细胞因子基因疗法分析抗人肿瘤作用和体内诱导人CTL。